Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:11 AM
Study NCT ID:
NCT05104905
Status:
WITHDRAWN
Last Update Posted:
2022-05-11
First Post:
2021-10-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Sponsor:
Faron Pharmaceuticals Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-07
Start Date Type:
ACTUAL
Primary Completion Date:
2022-01-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-28
Completion Date Type:
ACTUAL
First Submit Date:
2021-10-22
First Submit QC Date:
None
Study First Post Date:
2021-11-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-05
Last Update Post Date:
2022-05-11
Last Update Post Date Type:
ACTUAL